Histopathological investigation of glioblastomas resected under bevacizumab treatment

Ryota Tamura, Toshihide Tanaka, Keisuke Miyake, Yusuke Tabei, Kentaro Ohara, Oltea Sampetrean, Maya Kono, Katsuhiro Mizutani, Yohei Yamamoto, Yuichi Murayama, Takashi Tamiya, Kazunari Yoshida, Hikaru Sasaki

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

To date, no clinical observations have been reported for histopathological changes in human gliomas under antiangiogenic treatment. We collected six glioblastomas resected under bevacizumab treatment. Histopathological investigation was performed by hematoxilyn-eosin staining and immunohistochemistry for CD34, VEGF, VEGFR1/2, HIF-1α, CA9, and nestin as compared to eleven control glioblastomas to assess the differences in histological features, microvessel density, expression of VEGF and its receptors, tumor oxygenation, and status of glioma stem-like cells. In the six tumors resected under bevacizumab, microvascular proliferation was absent, and microvessel density had significantly decreased compared with that of the controls. The expressions of VEGF and its receptors were downregulated in two cases of partial response. HIF-1α or CA9 expression was decreased in five of the six tumors, whereas the decreased expression of these markers was noted in only one of the 11 control glioblastomas. The expression of nestin significantly decreased in the six tumors compared with that of the controls, with the remaining nestin-positive cells being relatively concentrated around vessels. We provide the first clinicopathological evidence that antiangiogenic therapy induces the apparent normalization of vascular structure, decrease of microvessel density, and improvement of tumor oxygenation in glioblastomas. These in situ observations will help to optimize therapy.

Original languageEnglish
Pages (from-to)52423-52435
Number of pages13
JournalOncotarget
Volume7
Issue number32
DOIs
Publication statusPublished - 2016 Aug 1

Fingerprint

Glioblastoma
Nestin
Microvessels
Vascular Endothelial Growth Factor Receptor
Neoplasms
Glioma
Therapeutics
Eosine Yellowish-(YS)
Vascular Endothelial Growth Factor A
Blood Vessels
Stem Cells
Down-Regulation
Immunohistochemistry
Bevacizumab
Staining and Labeling

Keywords

  • Bevacizumab
  • Glioma stem cell
  • Hypoxia
  • Neoadjuvant
  • Vascular normalization

ASJC Scopus subject areas

  • Oncology

Cite this

Histopathological investigation of glioblastomas resected under bevacizumab treatment. / Tamura, Ryota; Tanaka, Toshihide; Miyake, Keisuke; Tabei, Yusuke; Ohara, Kentaro; Sampetrean, Oltea; Kono, Maya; Mizutani, Katsuhiro; Yamamoto, Yohei; Murayama, Yuichi; Tamiya, Takashi; Yoshida, Kazunari; Sasaki, Hikaru.

In: Oncotarget, Vol. 7, No. 32, 01.08.2016, p. 52423-52435.

Research output: Contribution to journalArticle

Tamura, R, Tanaka, T, Miyake, K, Tabei, Y, Ohara, K, Sampetrean, O, Kono, M, Mizutani, K, Yamamoto, Y, Murayama, Y, Tamiya, T, Yoshida, K & Sasaki, H 2016, 'Histopathological investigation of glioblastomas resected under bevacizumab treatment', Oncotarget, vol. 7, no. 32, pp. 52423-52435. https://doi.org/10.18632/oncotarget.9387
Tamura, Ryota ; Tanaka, Toshihide ; Miyake, Keisuke ; Tabei, Yusuke ; Ohara, Kentaro ; Sampetrean, Oltea ; Kono, Maya ; Mizutani, Katsuhiro ; Yamamoto, Yohei ; Murayama, Yuichi ; Tamiya, Takashi ; Yoshida, Kazunari ; Sasaki, Hikaru. / Histopathological investigation of glioblastomas resected under bevacizumab treatment. In: Oncotarget. 2016 ; Vol. 7, No. 32. pp. 52423-52435.
@article{693d677380ed479f8eacc15474480c37,
title = "Histopathological investigation of glioblastomas resected under bevacizumab treatment",
abstract = "To date, no clinical observations have been reported for histopathological changes in human gliomas under antiangiogenic treatment. We collected six glioblastomas resected under bevacizumab treatment. Histopathological investigation was performed by hematoxilyn-eosin staining and immunohistochemistry for CD34, VEGF, VEGFR1/2, HIF-1α, CA9, and nestin as compared to eleven control glioblastomas to assess the differences in histological features, microvessel density, expression of VEGF and its receptors, tumor oxygenation, and status of glioma stem-like cells. In the six tumors resected under bevacizumab, microvascular proliferation was absent, and microvessel density had significantly decreased compared with that of the controls. The expressions of VEGF and its receptors were downregulated in two cases of partial response. HIF-1α or CA9 expression was decreased in five of the six tumors, whereas the decreased expression of these markers was noted in only one of the 11 control glioblastomas. The expression of nestin significantly decreased in the six tumors compared with that of the controls, with the remaining nestin-positive cells being relatively concentrated around vessels. We provide the first clinicopathological evidence that antiangiogenic therapy induces the apparent normalization of vascular structure, decrease of microvessel density, and improvement of tumor oxygenation in glioblastomas. These in situ observations will help to optimize therapy.",
keywords = "Bevacizumab, Glioma stem cell, Hypoxia, Neoadjuvant, Vascular normalization",
author = "Ryota Tamura and Toshihide Tanaka and Keisuke Miyake and Yusuke Tabei and Kentaro Ohara and Oltea Sampetrean and Maya Kono and Katsuhiro Mizutani and Yohei Yamamoto and Yuichi Murayama and Takashi Tamiya and Kazunari Yoshida and Hikaru Sasaki",
year = "2016",
month = "8",
day = "1",
doi = "10.18632/oncotarget.9387",
language = "English",
volume = "7",
pages = "52423--52435",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

TY - JOUR

T1 - Histopathological investigation of glioblastomas resected under bevacizumab treatment

AU - Tamura, Ryota

AU - Tanaka, Toshihide

AU - Miyake, Keisuke

AU - Tabei, Yusuke

AU - Ohara, Kentaro

AU - Sampetrean, Oltea

AU - Kono, Maya

AU - Mizutani, Katsuhiro

AU - Yamamoto, Yohei

AU - Murayama, Yuichi

AU - Tamiya, Takashi

AU - Yoshida, Kazunari

AU - Sasaki, Hikaru

PY - 2016/8/1

Y1 - 2016/8/1

N2 - To date, no clinical observations have been reported for histopathological changes in human gliomas under antiangiogenic treatment. We collected six glioblastomas resected under bevacizumab treatment. Histopathological investigation was performed by hematoxilyn-eosin staining and immunohistochemistry for CD34, VEGF, VEGFR1/2, HIF-1α, CA9, and nestin as compared to eleven control glioblastomas to assess the differences in histological features, microvessel density, expression of VEGF and its receptors, tumor oxygenation, and status of glioma stem-like cells. In the six tumors resected under bevacizumab, microvascular proliferation was absent, and microvessel density had significantly decreased compared with that of the controls. The expressions of VEGF and its receptors were downregulated in two cases of partial response. HIF-1α or CA9 expression was decreased in five of the six tumors, whereas the decreased expression of these markers was noted in only one of the 11 control glioblastomas. The expression of nestin significantly decreased in the six tumors compared with that of the controls, with the remaining nestin-positive cells being relatively concentrated around vessels. We provide the first clinicopathological evidence that antiangiogenic therapy induces the apparent normalization of vascular structure, decrease of microvessel density, and improvement of tumor oxygenation in glioblastomas. These in situ observations will help to optimize therapy.

AB - To date, no clinical observations have been reported for histopathological changes in human gliomas under antiangiogenic treatment. We collected six glioblastomas resected under bevacizumab treatment. Histopathological investigation was performed by hematoxilyn-eosin staining and immunohistochemistry for CD34, VEGF, VEGFR1/2, HIF-1α, CA9, and nestin as compared to eleven control glioblastomas to assess the differences in histological features, microvessel density, expression of VEGF and its receptors, tumor oxygenation, and status of glioma stem-like cells. In the six tumors resected under bevacizumab, microvascular proliferation was absent, and microvessel density had significantly decreased compared with that of the controls. The expressions of VEGF and its receptors were downregulated in two cases of partial response. HIF-1α or CA9 expression was decreased in five of the six tumors, whereas the decreased expression of these markers was noted in only one of the 11 control glioblastomas. The expression of nestin significantly decreased in the six tumors compared with that of the controls, with the remaining nestin-positive cells being relatively concentrated around vessels. We provide the first clinicopathological evidence that antiangiogenic therapy induces the apparent normalization of vascular structure, decrease of microvessel density, and improvement of tumor oxygenation in glioblastomas. These in situ observations will help to optimize therapy.

KW - Bevacizumab

KW - Glioma stem cell

KW - Hypoxia

KW - Neoadjuvant

KW - Vascular normalization

UR - http://www.scopus.com/inward/record.url?scp=84982296435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982296435&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9387

DO - 10.18632/oncotarget.9387

M3 - Article

C2 - 27244880

AN - SCOPUS:84982296435

VL - 7

SP - 52423

EP - 52435

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -